Q: What do you think of AMN as a healthcare holding?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Any thoughts on this medical device company?
Offers an FDA approved alternative for those dealing with sleep apnea.
Offers an FDA approved alternative for those dealing with sleep apnea.
Q: any idea why stock is down on big volume?
Q: your thoughts on recent Q3 results. worth sticking with this company or can you suggest alternative investment.
thanks
Don
thanks
Don
Q: Hello 5i , could I have your comments on Kodiak Sciences.
Its momentum is amazing. Any red flags?
Thanks
Dave
Its momentum is amazing. Any red flags?
Thanks
Dave
Q: Hi 5i Team,
Today analyst at Oppenheimer issues a report which commented a very bearish take on Amarin
Corp stock , arguing it will fall to 7.00 within 18 months due to higher cost in sale. This resulted a 15% drop at time of writing.
I am holding this stock for a few months , should I hold , sell or buy more?
What is your take? Are you still positive on this stock?
Thank you for your professional advice and assistance as always.
arguing
Today analyst at Oppenheimer issues a report which commented a very bearish take on Amarin
Corp stock , arguing it will fall to 7.00 within 18 months due to higher cost in sale. This resulted a 15% drop at time of writing.
I am holding this stock for a few months , should I hold , sell or buy more?
What is your take? Are you still positive on this stock?
Thank you for your professional advice and assistance as always.
arguing
Q: mdt reported today your thoughts please Gary
Q: Hello, A couple of well-respected advisors have recently recommended this stock on BNN Market Place. I read your opinion on this stock in October which was not positive. Has your opinion changed?
Q: Hi 5i Team,
Your comment on Bellus Health’s earning and it’s future outlook please.
Thank you for your professional service and advice as always.
Your comment on Bellus Health’s earning and it’s future outlook please.
Thank you for your professional service and advice as always.
Q: Does GUD's precipitous drop in share price indicate that the market believes the acquisition of Biotoscana was not a good investment? How solid is Biotoscana? Are some of their products fit for the US/CDN markets? South American market? Your opinion is always appreciated. Thanks. Gaston
Q: I know you have liked this stock in the past. It has been relatively flat over the last year (bouncing up and down) How do you feel about it now and going forward? Is there a better risk/reward trade off in the space?
Thanks!
Thanks!
Q: Can you comment about this US drug Co. developing immuno-medicines for Cancer.
Q: Hi 5i team,
Back to AMRN. I thought they hit a home run yesterday with a unanimous (16 to 0) vote of the Advisory Committee to approve an expanded label use of Vascepa for treating various heart-related conditions, which should give them access to a much larger patient population base. However, the market is not so sure as the response is very muted at least so far today, and that may change. I took a small position to manage risk as I expected a big move one way or the other. I recognize this still has to go to the full FDA in a few weeks, but I understand that the FDA seldom overturns a strong endorsement of the AdCom. Am I missing something here in the muted market response?
Thanks again.
Dave
Back to AMRN. I thought they hit a home run yesterday with a unanimous (16 to 0) vote of the Advisory Committee to approve an expanded label use of Vascepa for treating various heart-related conditions, which should give them access to a much larger patient population base. However, the market is not so sure as the response is very muted at least so far today, and that may change. I took a small position to manage risk as I expected a big move one way or the other. I recognize this still has to go to the full FDA in a few weeks, but I understand that the FDA seldom overturns a strong endorsement of the AdCom. Am I missing something here in the muted market response?
Thanks again.
Dave
Q: Hi there, it looks like the market likes the results out of Savaria this morning. It's been stuck in a range for quick sometime. Is this the start of a breakout? Would you be comfortable increasing this to a full position from half at this point? Thank you!
Q: Please comment on Q.Txs for u usual great services & views
Q: I have a half position in GUD. Would this be a good time to top up to a full position?
Q: FDA apparently has positive views on AMARIN's new drug Vascepa so approval for broad use seems likely; hence the recent pop. How much more upside does the stock have in the medium term.
Thanks for your insight.
Ian
Thanks for your insight.
Ian
Q: Please comment on Q today.Thanks for u usual great services & views
Q: Hi 5i team,
This is a further question on healthcare and their binary outcomes on drug trials and approvals. I did buy MDT by the way based on its growth prospects and little or no dependence on drug approvals. This question is on AMRN and more generally the FDA approval process. AMRN has an upcoming date with the FDA on November 14th. From a business site, I quote “The Adcom review of the sNDA for Vascepa on its cardioprotective benefit is scheduled for November 14, 2019 with PDUFA planned for December 28, 2019”. What does that mean and how does one go about handicapping the odds of FDA approval or not? If this is largely a coin flip, then I will pass. If it is a progression towards likely approval, I may take a small position. I also understand that AMRN will be subject to a trading halt on Thursday while the review process is underway.
Thanks again for your insight into AMRN and the FDA approval process.
Dave
P.S. I notice that NXTC is down over 50% in the pre-market, a stock you mentioned in the FP for its crazy run last week. I thought tech stocks were volatile. They trade like utilities compared to drug stocks!
This is a further question on healthcare and their binary outcomes on drug trials and approvals. I did buy MDT by the way based on its growth prospects and little or no dependence on drug approvals. This question is on AMRN and more generally the FDA approval process. AMRN has an upcoming date with the FDA on November 14th. From a business site, I quote “The Adcom review of the sNDA for Vascepa on its cardioprotective benefit is scheduled for November 14, 2019 with PDUFA planned for December 28, 2019”. What does that mean and how does one go about handicapping the odds of FDA approval or not? If this is largely a coin flip, then I will pass. If it is a progression towards likely approval, I may take a small position. I also understand that AMRN will be subject to a trading halt on Thursday while the review process is underway.
Thanks again for your insight into AMRN and the FDA approval process.
Dave
P.S. I notice that NXTC is down over 50% in the pre-market, a stock you mentioned in the FP for its crazy run last week. I thought tech stocks were volatile. They trade like utilities compared to drug stocks!
Q: Can I get your opinion on Medical Facilities ? The stock price has been crushed ....any chance of a rebound in 2020?